Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort Study

Chun-Tse Hung, Chen-Yen An, Chi-Won Suk, Ting-Wei Lee, Shun-Hsing Hung · 2026

Read Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort Study by Chun-Tse Hung, Chen-Yen An, Chi-Won Suk, Ting-Wei Lee, Shun-Hsing Hung (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13565390.txt.

Description

Chun-Tse Hung and four co-authors compare two diabetes drugs head to head for asthma flare risk in people who have both conditions, in this 2026 study. Both drugs act on gut hormone pathways, and one, tirzepatide, adds a second target. Records came from a large United States research network, covering patients who started either drug between 2022 and 2024.

After matching, over eight thousand patients stood in each group. Flare rates over twelve months were nearly identical, about eleven percent in both. Rescue inhaler use ran slightly lower with tirzepatide, while steroid use matched. Subgroup and sensitivity checks agreed. The authors conclude the dual drug shows no edge on flares, and they call for randomized trials to settle what these drug classes can do for asthma.

Catalog record

CREATORChun-Tse Hung, Chen-Yen An, Chi-Won Suk, Ting-Wei Lee, Shun-Hsing Hung
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13565390

Browse the full library · About the Tower of Babel